Article

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment

2017-05-28

Abstract excerpt

The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Interleukin-6 (IL-6) and downstream JAK/STAT signaling are thought to be central components of these microenvironment-induced phenotypes. In a prior drug repurposing screen, we identified tofacitinib, a pan-JAK inhibitor FDA-approved for rheumatoid arthritis, as an agent that may reverse the tumor-s...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5da92acf-a4be-59ed-817d-dc671dd2badf
DOI: 10.1101/143206

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironmentDOI 10.1101/143206Read

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple MyelomaSemantic proximity Read

Novel Interleukin-6 Inducible Gene PDZ-Binding Kinase Promotes Tumor Growth of Multiple Myeloma CellsSemantic proximity Read

The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination StrategiesSemantic proximity Read

Elevated levels of Protein S in Multiple Myeloma bone marrow microenvironment regulate tumor progression and bone diseaseSemantic proximity Read

Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug ResistanceSemantic proximity Read

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myelomaSemantic proximity Read

Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunitiesSemantic proximity Read

Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYCSemantic proximity Read

Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapySemantic proximity Read

Romosozumab Safely Restores Bone Mass in Multiple Myeloma via Osteoblast Reprogramming: A Phase IIa StudySemantic proximity Read

Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells.Semantic proximity Read

Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myelomaSemantic proximity Read